International forum of allergy & rhinology
Medicaid Coverage and Utilization for Novel Therapies for Chronic Rhinosinusitis With Nasal Polyposis.
Eric R Ramos, Sriram Satyavolu, Ashley L Miller, George A Scangas, Zachary M Soler, Rodney J Schlosser, Yufan Lin, Vinay K Rathi
Published: 202610.1002/alr.70109
Abstract
KEY POINTS: Most state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.